CSL lifts H1 profit 24% to $US627m
Market watch top headlines
Australian reports
- Aust markets: Aust stocks lower as $32b wiped off market
- Aust dollar report: $A falls as $US soars
- Aust credit close: Aust bonds weaker on Bernanke comments
World reports
- World commodities: Commodities markets summary
- World markets: International markets roundup
AAP
2013-02-13
CSL's first half profit is up 24 per cent and the company expects to lift its full year profit by about 20 per cent.
The blood products and vaccine maker made a net profit of $US627 million in the six months to December 31, up from $483 million in the previous corresponding period.
Sales revenue rose seven per cent to $US2.5 billion.
In November, CSL forecast a 20 per cent rise in its full year net profit, from the previous year's $US1.02 billion.
Chief executive Dr Brian McNamee said that while global business conditions remain mixed, CSL re-affirmed its upgraded profit outlook.
"We continue to anticipate fiscal year 2013 net profit after tax to grow by approximately 20 per cent at constant currency," he said in a statement on Wednesday.
"Earnings per share growth will again exceed profit growth as shareholders benefit from the ongoing effect of past and current capital management initiatives.
"This year, we anticipate earnings per share growth of approximately 24 per cent."
